CA2311679A1 - Use of a soluble recombinant human cd40l protein for inhibiting in vivo immune response - Google Patents
Use of a soluble recombinant human cd40l protein for inhibiting in vivo immune response Download PDFInfo
- Publication number
- CA2311679A1 CA2311679A1 CA002311679A CA2311679A CA2311679A1 CA 2311679 A1 CA2311679 A1 CA 2311679A1 CA 002311679 A CA002311679 A CA 002311679A CA 2311679 A CA2311679 A CA 2311679A CA 2311679 A1 CA2311679 A1 CA 2311679A1
- Authority
- CA
- Canada
- Prior art keywords
- recombinant human
- soluble recombinant
- alloimmune response
- human cd40l
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
Abstract
The invention relates to a method for inhibiting in vivo immune response and to the use of a soluble recombinant human CD40L or a sequence within said soluble recombinant human CD40L containing the active binding site with CD40 for inhibiting an immune response. The invention also relates to a mouse model of human alloimmunization for testing in vivo effects of an immunotherapy or inhibition of a human antibody response.
Claims (26)
1. Use of a soluble recombinant human CD40L or a functional fragment thereof containing the active binding site of CD40 and capable of binding thereto, for inhibiting an alloimmune response.
2. The use of claim 1, wherein the soluble recombinant human CD40L has a sequence comprised in amino acids 108 to 261 of sequence set forth in SEQ ID
NO:1.
NO:1.
3. The use of claim 1, wherein the alloimmune response is a human anti-HLA alloimmune response.
4. Use of a soluble recombinant human CD40L or a functional fragment thereof containing the active binding site of CD40 and capable of binding thereto, for inhibiting T cell function in an alloimmune response.
5. The use of claim 4, wherein the soluble recombinant human CD40L has a sequence comprised in amino acids 108 to 261 of sequence set forth in SEQ ID
NO:1.
NO:1.
6. The use of claim 4, wherein the alloimmune response is a human anti-HLA alloimmune response.
7. The use of claim 4, for treating or preventing a disease selected from the group consisting of systemic lupus erythematosus (SLE), sjögren's syndrome, sleroderma myositis, Raynaud's syndrome, type 1 diabetes, arthritis and rheumatoid arthritis, inflammatory bowel disease, uveitis, myesthenia gravis, multiple sclerosis, idiopathic thrombocytopenic purpura and graft vs host disease as well as allergies which are dependent on T cells.
8. Use of a soluble recombinant human CD40L or a functional fragment thereof containing the active binding site of CD40 and capable of binding thereto, for the preparation of a medicament for immunotherapy.
9. Use of a soluble recombinant human CD40L or a functional fragment thereof containing the active binding site of CD40 and capable of binding thereto, for the preparation of a medicament for treating or preventing a disease selected from the group consisting of systemic lupus erythematosus (SLE), sjögren's syndrome, sleroderma myositis, Raynaud's syndrome, type 1 diabetes, arthritis and rheumatoid arthritis, inflammatory bowel disease, uveitis, myesthenia gravis, multiple sclerosis, idiopathic thrombo-cytopenic purpura and graft vs host disease as well as allergies which are dependent on T cells.
10. Use of an immunodeficient mouse model of human alloimmunization for testing in vivo effects of an immunotherapy or inhibition of a human antibody response, said mouse model being an immunodeficient mouse, reconstituted with human peripheral blood lymphocytes (PBL) from donors.
11. The use of claim 10, wherein the immunodeficient mouse is .gamma.-irradiated and asialoGM1 treated for enhancing cellular engraftment.
12. The use of claim 10, wherein the donors are sensitized to HLA antigens.
13. A method for inhibiting an alloimmune response in a patient, comprising the step of administering a therapeutically effective amount of a soluble recombinant human CD40L or a functional fragment thereof containing the active binding site of CD40 and capable of binding thereto.
14. The method of claim 13, wherein the soluble recombinant human CD40L has a sequence comprised in amino acids 108 to 261 of sequence set forth in SEQ ID
NO:1.
NO:1.
15. The method of claim 13, wherein the alloimmune response is a human anti-HLA alloimmune response.
16. A method for inhibiting T cell function in an alloimmune response in a patient, comprising the step of administering a therapeutically effective amount of a soluble recombinant human CD40L or a functional fragment thereof containing the active binding site of CD40 and capable of binding thereto.
17. The method of claim 16, wherein the soluble recombinant human CD40L has a sequence comprised in amino acids 108 to 261 of sequence set forth in SEQ ID
NO:1.
NO:1.
18. The method of claim 16, wherein the alloimmune response is a human anti-HLA alloimmune response.
19. The method of claim 16, for treating or preventing a disease selected from the group consisting of systemic lupus erythematosus (SLE), sjogren's syndrome, sleroderma myositis, Raynaud's syndrome, type 1 diabetes, arthritis and rheumatoid arthritis, inflammatory bowel disease, uveitis, myesthenia gravis, multiple sclerosis, idiopathic thrombocytopenic purpura and graft vs host disease as well as allergies which are dependent on T cells.
20. Use of a soluble recombinant human CD40L or a functional fragment thereof containing the active binding site of CD40 and capable of binding thereto, for the manufacture of a medicament for inhibiting an alloimmune response.
21. The use of claim 20, wherein the soluble recombinant human CD40L has a sequence comprised in amino acids 108 to 261 of sequence set forth in SEQ ID
NO:1.
NO:1.
22. The use of claim 20, wherein the alloimmune response is a human anti-HLA alloimmune response.
23. Use of a soluble recombinant human CD40L or a functional fragment thereof containing the active binding site of CD40 and capable of binding thereto, for the manufacture of a medicament for inhibiting T
cell function in an alloimmune response.
cell function in an alloimmune response.
24. The use of claim 23, wherein the soluble recombinant human CD40L has a sequence comprised in amino acids 108 to 261 of sequence set forth in SEQ ID
NO:1.
NO:1.
25. The use of claim 23, wherein the alloimmune response is a human anti-HLA alloimmune response.
-32a-
-32a-
26. The use of claim 23, wherein the medicament is a medicament for treating or preventing a disease selected from the group consisting of systemic lupus erythematosus (SLE), sjogren's syndrome, sleroderma myositis, Raynaud's syndrome, type 1 diabetes, arthritis and rheumatoid arthritis, inflammatory bowel disease, uveitis, myesthenia gravis, multiple sclerosis, idiopathic thrombocytopenic purpura and graft vs host disease as well as allergies which are dependent on T cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2311679A CA2311679C (en) | 1997-11-28 | 1998-11-27 | Use of a soluble recombinant human cd40l protein for inhibiting in vivo immune response |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002223225A CA2223225A1 (en) | 1997-11-28 | 1997-11-28 | Method for inhibiting in vivo immune response |
| CA2,223,225 | 1997-11-28 | ||
| CA2311679A CA2311679C (en) | 1997-11-28 | 1998-11-27 | Use of a soluble recombinant human cd40l protein for inhibiting in vivo immune response |
| PCT/CA1998/001105 WO1999027948A2 (en) | 1997-11-28 | 1998-11-27 | Use of soluble recombinant human cd40l protein for inhibiting in vivo immune response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2311679A1 true CA2311679A1 (en) | 1999-06-10 |
| CA2311679C CA2311679C (en) | 2011-02-15 |
Family
ID=25679881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2311679A Expired - Fee Related CA2311679C (en) | 1997-11-28 | 1998-11-27 | Use of a soluble recombinant human cd40l protein for inhibiting in vivo immune response |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2311679C (en) |
-
1998
- 1998-11-27 CA CA2311679A patent/CA2311679C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2311679C (en) | 2011-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harding et al. | Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation | |
| ES2237757T3 (en) | METHODS TO INDUCE THE TOLERANCE OF CELLS T TO A TISSUE OR ORGAN GRAFT. | |
| ATE415173T1 (en) | PAN DR BINDING PROTEINS TO INCREASE THE IMMUNE RESPONSE | |
| CN110935025A (en) | Agents for treating and/or preventing autoimmune diseases and for forming regulatory T cells | |
| DE69435261D1 (en) | HUMAN RECIPE H4-1BB | |
| JPH08505365A (en) | Treatment of autoimmune and inflammatory diseases | |
| CA2422294A1 (en) | Modulation of il-2- and il-15-mediated t cell responses | |
| EA201070623A1 (en) | CONSTRUCTION OF POLYPEPTIDES OF SINGLE-DOMAIN ANTIBODIES, APPLICATION OF THE COMPOSITION CONTAINING IT AND THE METHOD OF TREATING RHEUMATOID ARTHRITIS | |
| NZ508381A (en) | Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5) | |
| EP2254588B1 (en) | Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis | |
| EA003944B1 (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
| EP1003552A4 (en) | LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION | |
| IL93397A (en) | Pancreatic islet cell antigen protein or peptides, their preparation by molecular cloning, their use in the diagnosis of insulin dependent diabetes mellitus and pharmaceutical compositions comprising said antigens | |
| CA2110055C (en) | T cell receptor peptides as therapeutics for immune-related disease | |
| US6995237B1 (en) | Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions | |
| WO2016022900A1 (en) | Use of ligands for the programmed cell death receptor conjugated to solid supports for the expansion of human regulatory t cells | |
| US7256254B2 (en) | Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions | |
| Riemekasten et al. | Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells | |
| EP1964854A2 (en) | Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions | |
| WO1996018646A3 (en) | Heat shock protein peptides and methods for modulating autoimmune central nervous system disease | |
| Yan et al. | Cytokines, IgG subclasses and costimulation in a mouse model of thyroid autoimmunity induced by injection of fibroblasts co‐expressing MHC class II and thyroid autoantigens | |
| EP1404362B1 (en) | Signal-1/signal-2 bifunctional peptide inhibitors | |
| Briand et al. | Emerging peptide therapeutics for inflammatory autoimmune diseases | |
| Rodríguez‐Álvarez et al. | d‐Amino acid substitutions and dimerization increase the biological activity and stability of an IL‐15 antagonist peptide | |
| CA2311679A1 (en) | Use of a soluble recombinant human cd40l protein for inhibiting in vivo immune response |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20171127 |